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Introduction
Allergic dermatitis is a genetic-based skin condition 
affecting an increasing number of dogs (1). A more 
efficient treatment approach is often multimodal, 
including a special focus on skin barrier condition, from 
which many pruritic triggers depend as well as common 
complications (2).
Like in humans, for the development of canine atopic 
dermatitis (cAD), defects in the lipid and protein 
constitution of the skin may contribute to the reduction of 
the skin barrier function, favoring the in depth 
penetration of allergens (3) and stimulating the immune 
response as an outside/inside - inside/outside paradigm
(4).
Aim
Evaluating the specific role of skin barrier-directed 
reestablishing treatment in allergic dermatitis clinical
improvement
Materials and Methods
Five dogs with allergic dermatitis were selected from an allergy outpatient 
consultation following owners’ informed consent approved by an ethics 
committee. Patients were subjected to CADESI-4 evaluation and specific 
diagnosis for atopy and/or food allergy, including IDT. 
Skin biopsies were performed from a non-infected inflamed and adjacent non-
affected area, and conserved in 4% buffered formaldehyde. Follow up lasted for 
2-3 months, applying avoidance measures directed to the implicated allergen 
sources and treating with a phytosphingosine-containing shampoo/lotion, 
according to the manufacturer’s directions. Reassessment was done each 10-15 
days with CADESI-4 and further IDT and skin biopsies performed at the end. 
Skin samples were histologically processed including staining with toluidine blue 
for mastocytes and van Gieson for collagen fibers. Thickness of the non-
keratinized epidermal layer and stratum corneum as well this lamina 
organization were accessed and scored 1-5. Mast cell density and integrity, and 
collagen density in the dermal layer were also assessed and scored (%). Normal 
(N) and lesion (L) data, before and after treatment, were compared.
Results
Three patients showed evident clinical improvement (No. 
2, 3, and 5) with (10, 19 and 11 respective decrease in 
CADESI-4 scores), 1 moderately (No. 4) with (3 in CADESI-
4) and 1 (No. 1) did not (1 in CADESI-4)
IDT results did not vary from before to after treatment.
Non-keratinized epidermal layer/stratum corneum
thickness ranged respectively 12/4 (N) to 330/300 μm (L) 
before treatment and 10/4 (N) to 120/120 μm (L) after 
treatment (Fig.).
Lamina cornea organization tended to increase with no 
clear change in collagen fibers (vG – Fig.). 
Mast cell density and integrity improved in the 
recovered patients with a mean drop of 15.2% and an 
increase of 22.8%, respectively (TB – Fig.).
Conclusions
Skin barrier-directed reestablishing measures in allergic 
dermatitis:
1. Allow for an effective and significant clinical improvement, 
even as a single choice approach. 
2. Should be considered as non-side-effect procedures, 
especially when a curative immunological approach is not 
possible or effective.
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